Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.69 |
| ▸ | CCR5 | P51681 | 5/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243378 | 0.92 | SIGMAR1 (0.72) | SIGMAR1CCR5 | |
| SCHEMBL13929356 | 0.90 | SIGMAR1 (0.69) | SIGMAR1CCR5L3MBTL1 | |
| SCHEMBL13929321 | 0.89 | SIGMAR1 (0.71) | SIGMAR1CCR5CNR1CNR2L3MBTL1 | |
| SCHEMBL13929351 | 0.89 | L3MBTL1 (0.69) | SIGMAR1CCR5L3MBTL1 | |
| SCHEMBL13929349 | 0.89 | CCR5 (0.72) | SIGMAR1CCR5 | |
| SCHEMBL3671761 | 0.87 | SIGMAR1 (0.59) | SIGMAR1CCR5L3MBTL1 | |
| SCHEMBL13929467 | 0.87 | SIGMAR1 (0.59) | SIGMAR1CCR5 | |
| SCHEMBL13929211 | 0.86 | SIGMAR1 (0.69) | SIGMAR1CCR5 | |
| SCHEMBL13929323 | 0.86 | CCR5 (0.73) | SIGMAR1CCR5 | |
| SCHEMBL3641995 | 0.86 | CCR5 (0.67) | SIGMAR1CCR5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | SIGMAR1 129/4885CCR5 2/4885CNR1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.